Today's Date: March 29, 2024
Parkland Corporation Announces the Results of the 2024 Annual General Meeting of Shareholders   •   Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures   •   Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages   •   Amerex Group Unveils Red Carter Swimwear's Revitalized Collection   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors   •   Naropa University Launches Pioneering Psychedelic Minor     •   Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.   •   e.l.f. Cosmetics Debuts TikTok Shop Super Brand Day   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS   •   Equalpride Partners with TransLash Media for Trans Day of Visibility, Amplifying Voices of Black Trans Femmes in the Arts   •   YMCA of the USA Partners With Old Spice To Increase High School Graduation Among Boys And Young Men Of Color Through Mentorship   •   Jamieson Wellness Publishes Inaugural Sustainability Impact Report   •   Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023   •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   Make-A-Wish and celebrity wish granters announce goal to recruit 1 million people to become "WishMakers"   •   Coachella Concerned That People Have Sex, Says AHF   •   National University Receives 2024 Military Friendly® Gold Designation   •   Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment   •   Visit Visalia Recognizes Autism Awareness Month in April
Bookmark and Share

Paragonix Announces First Pediatric Use of LUNGguard™ System in Groundbreaking “Time Shift” Lung Transplantati

CAMBRIDGE, Mass. , February 08 /Businesswire/ - Paragonix Technologies, Inc., a leading organ preservation provider, announced today a pioneering lung transplantation case in which donor lungs procured overnight were preserved with the LUNGguard Donor Lung Preservation System, allowing for next day transplant surgery led by Prof. Dr. Laurens Ceulemans at UZ Leuven in Belgium. UZ Leuven Hospital, one of the most innovative and respected transplant centers in Europe, recently completed this landmark case, also marking the first use of the LUNGguard System in a pediatric lung transplant case anywhere in the world.

Overnight organ transplantation has been shown in clinical studies to be associated with a reduction in post-operative outcomes, including long term survival.1,2 A 2020 clinical study of 740 patients found overnight lung transplantations was associated with higher risks of major postoperative adverse events (p=0.019), lower 5-year survival rates (p=0.024), and lower 5- year bronchiolitis obliterans syndrome–free survival (p=0.013).1

“The case was a bilateral lobar transplant, which is a complex procedure that should be avoided during nigh-time,” explained Prof. Dr. Ceulemans. “The LUNGguard System enabled us to safely prolong the ischemic time. This time-shift allows more in-house expertise from the whole team, including cardiac surgeons, anesthesiologists and scrub nurses. The procedure went fine, and the patient is home without oxygen, able to breathe like never before.”

Disclaimer: Extension of ischemic time in Paragonix LUNGguard should only be extended after assessment by a qualified attending physician.

The Paragonix LUNGguard™ Donor Lung Preservation System is the only FDA cleared and CE marked preservation device for hypothermic donor lung transportation. The LUNGguard incorporates Paragonix proprietary cooling technology to ensure thermal protection at 4-8°C for up to 40 hours for all donor lungs while providing a rigid and protective structure for physical safety. To date, LUNGguard has been used on over 400 lung transplant cases globally. Paragonix administers the largest post market clinical registry investigating the use of Advanced Organ Preservation compared to ice transport, with over 220 active enrollments for lung and over 1,500 active enrollments for heart.

UZ Leuven is one of several centers actively evaluating the use of LUNGguard technology as part of a strategy to address the logistical and clinical challenges of transplant procedures that are otherwise difficult to schedule. If implemented more broadly, such a strategy has the potential for centers to access donor lungs from further distances and entertain more matches for their waitlist patients given the flexibility with scheduled procedures, ultimately increasing the options for donor lungs available for their patients.

“We are excited to see our hypothermic technology used in this exciting new use case and look forward to seeing the impact this innovative approach has on clinical outcomes,” said Dr. Lisa Anderson, CEO and President of Paragonix. ”Overnight transplantation places tremendous stress on clinical staff and to be involved in providing a possible alternative is beyond thrilling. The physical and mental wellness of transplant surgeons and their staff are always at the forefront of our product development process and anything we can do to improve the efficiencies of these programs, we will continue to aggressively pursue.“

About Paragonix Technologies

Paragonix Technologies is a leading provider of Advanced Organ Preservation (AOP) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ in transit. Every Paragonix AOP device natively integrates with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution.

Paragonix LUNGguard™ Indications for Use

The Paragonix LUNGguard™ (LUNGguard™) is intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs.

The intended organ storage time for LUNGguard™ is up to 8 hours. Donor lungs exceeding clinically accepted static hypothermic preservation times should be evaluated by the transplant surgeon to determine transplantability in accordance with accepted clinical guidelines and in the best medical interest of the intended recipient.

For important safety information on the Paragonix LUNGguard System please visit: Important Safety Information

Follow us on Twitter: @ParagonixSherpa

Connect with us on LinkedIn: Paragonix Technologies

Like Us on Facebook: Paragonix SherpaPak

References

  1. Yang et al. The Annals of Thoracic Surgery, 2020.
  2. Emmanouilidis et al, J Transplant, 2017.
  3. Hartwig et al., ISHLT Presentation 2022, Data on file

L-411, Rev 1


STORY TAGS: Science, Other Science, Research, Health, FDA, Medical Devices, Health Technology, Clinical Trials, Business Update, Product/Service, Massachusetts, Belgium, Europe, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News